Pluvicto and Lutathera 5 Year BPA
Award Notice Posted
- Solicitation number
- HT941026AE002
- Agency
-
Defense Health Agency
Department of Defense
- Awarded
- to Novartis Pharmaceuticals Corporation
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HT941026AE002 Federal IDV award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Diego, California 92134, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency has awarded a five-year Blanket Purchase Agreement (BPA) to Novartis Pharmaceuticals Corporation under contract number HT941026AE002, effective January 29, 2026, for the supply of two injectable radiopharmaceutical products used to treat prostate cancer: LUTATHERA (lutetium Lu 177 dotatate) at $41,805.80 per unit and PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) at $34,294.26 per unit. The BPA establishes an estimated contract value of $5,000,000 with a maximum purchase limitation of $500,000 per individual call order, covering the period from March 2, 2026 through March 1, 2031, with all products to be delivered to Naval Medical Center San Diego's Nuclear Medicine Division in San Diego, California. This sole-source acquisition was justified based on Novartis's exclusive distribution rights and the lack of alternative radiopharmaceuticals available to treat the specified cancer indication, with no responses received during the posted Notice of Intent to Sole Source period.
Notice text
Contract Award Pluvicto and Lutathera 5 Year BPA
Awarded contract HT941026AE002 to Novartis Pharmaceuticals Corporation for 5000000.00 on 2026-01-29.
Files
| File | Type | Posted |
|---|---|---|
| HT941026N0009 Control Number FY26-0473 JA v4_Redacted.pdf | ||
| Contract HT941026AE002 - Signed.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity